Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
MINNEAPOLIS - Medical device maker Medtronic Inc. said Monday it has commenced a global study comparing the company's Endeavor drug-eluting stent against Abbott Laboratory's competing Xience V drug-eluting stent.
The first patients were implanted with the device in Europe over the last two weeks.
The trial, called RESOLUTE III, will enroll a total of 2,300 patients.
Although the Endeavor stent won European regulatory approval in October, the coronary stent has yet to be approved in the U.S. Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Shares of Medtronic rose 11 cents to $47.90 in morning trading.
The HTC Droid Eris will be available alongside the Motorola Droid this Friday, N...
At first I was going to post this story from the UK Telegraph as an interesting piece... food for thought if you will... with the tag that this t...
Online distributor for point of sale equipment, TYSSO and Pegasus.
Partners 
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
-0.45
0.48
